<a href="https://laohu8.com/S/QTTB">Q32 Bio Inc.</a> Receives Nasdaq Notice for Non-Compliance with Listing Requirements Due to Stockholders' Equity Deficit
Q32 Bio Inc. has announced that it received a notice from the Nasdaq Stock Market LLC on May 19, 2025, indicating that the company is no longer in compliance with the minimum stockholders' equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market. The company's recent financial report showed a stockholders' equity deficit of approximately $4.0 million. Additionally, Q32 Bio failed to meet alternative criteria, such as a market value of listed securities of $35.0 million or net income from continuing operations of $0.5 million. This situation arose partly due to the accounting impact of re-acquiring bempikibart from Amgen Inc. Q32 Bio now has 45 days to submit a compliance plan to Nasdaq. If accepted, Nasdaq may grant an extension of up to 180 days for Q32 Bio to meet the listing requirements. Meanwhile, the company's stock will continue trading on Nasdaq under the symbol "QTTB."
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-125435), on May 23, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。